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Conclusion 
In our prospective cohort, we observed a correlation 
between acute toxicity and pain, impairment in global 
health status and general QoL. DVH analysis of oral mucosa 
and its subsites accurately predicts acute oral mucosa 
toxicity We were also able to assess the predictive value 
of clinical parameters for OM. Further studies will be 
needed to understand clinical relevance, implement daily 
practice and improve results. 
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Purpose or Objective 
Shortening the overall treatment time without increasing 
acute reactions is one of the major aims in radiotherapy 
for locally advanced head and neck cancer (LAHNC). 
Volumetric modulated arc therapy (VMAT) with 
Simultaneous Integrated Boost (SIB) showed improvements 
in the outcome and pattern of toxicity. Aim of this work is 
to evaluate the toxicity of patients presenting LAHNC, 
after VMAT-SIB treatment in two fractionation schemes of 
30 and 33 fractions. 
Material and Methods 
Two groups of LCHNC patients were selected: the first, 
named 33fx, of 98 patients who received 69.96 and 54.45 
Gy in SIB in 33 fractions, between April 2009 and 
November 2015; the second, named 30fx, of 48 patients 
who received 66.0 and 54.0 Gy in SIB in 30 fractions, 
between March 2016 and January 2018. All the patients 
were treated with VMAT-SIB. Target volumes were 
delineated as CTV adding 1 cm margin to GTV for primary 
tumour, and according to the international guidelines for 
nodal regions; a CTV to PTV 5 mm isotropic margin was 
added for the 33fx group, and 3 mm margin for the 30fx 
group. Acute toxicity was graded according to CTCAE 3 for 
skin, salivary, mucosal, dysphagia. Doses from DVHs for 
each patient were recorded and analysed to determine 
possible correlations between dose to critical structures 
(parotids, oral cavity, submandibular glands and 
constrictor muscles) and toxicity grade. 
Results 
The dosimetric results showed a significant reduction of 
the mean doses to the main critical structures when 
reducing the number of fraction (and the total dose) as 
well as the CTV to PTV margin. To the parotids, the mean 
doses were assessed as 28.0±0.7 and 21.8±0.9 Gy for 33fx 
and 30fx groups, respectively; to the oral cavity they were 
46.3±0.9 and 40.9±1.4 Gy; for the constrictor muscles 
59.5±0.5 and 52.1±0.9 Gy. Errors are the standard error of 
the mean. 
Acute mucosal toxicity was reported as G1 in 28.6/27.1% 
(33fx/30fx) of the cases, G2 in 45.9/41.7%, G3 in 
8.2/4.2%. Acute dysphagia was recorded as G1 in 
22.4/18.8% of the patients in the 33fx/30fx groups, G2 in 
25.5/56.3%, and G3 in 7.1/4.2%. Acute salivary toxicity 
was G1 in 25.5/8.3% of the cases, G2 in 3.1/6.3%, and G3 
in 1.0/0.0%. The toxicity profile, in favour of the 30fx 
group, was significant only for dyspagia (p<0.01, test t).  
The highly significant difference in the mean doses was 
not translating to the same high degree of significance in 
the toxicity profile. 
Conclusion 
Treatment of LAHNC with 30 fractions radiotherapy and 3 
mm of margin seems to be advantageous for the decreased 
mean doses to the major organs at risk. However, 
significant toxicity benefit was only demonstrated in the 
reduction of dysphagia. 
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Purpose or Objective 
Salivary gland hypofunction and xerostomia are prominent 
complications of conventional radiotherapy (RT) of head 
and neck cancer (HNC), having considerable negative 
impact on the patients’ quality of life. It is therefore 
important to assess the salivary gland function in these 
patients for diagnostic and management purposes. 
The aim of this study is to investigate use of diffusion-
weighted magnetic resonance imaging (DWI) in the 
assessment of radiation-induced microstructural changes 
of the parotid glands in terms of apparent diffusion 
coefficients values (ADC), compared to physiological 
changes in terms of measurements of whole salivary flow 
rates.  It is hypothesized that use of combined methods 
for assessment of parotid gland function, provides further 
insight into the factors that can predict xerostomia. 
Material and Methods  
Five patients with HNC who have completed their RT 
course were assessed in this pilot study.  The patients 
were examined before the first RT fraction (scan 1), after 
completion of the RT course (scan 2) and one year after 
completion of the RT course (scan 3).  Unstimulated (at 
rest) and gustatory-stimulated DWI examinations were 
performed on a 1T MRI system using the DWIBS sequence. 
Whole-volume region of interest (ROI) method was used 
for delineation of parotid glands. To suppress perfusion 
and salivary flow effects high b-values (400, 600 and 800 
s/mm²) were used for ADC calculation using a mono 
exponential fit. Unstimulated and chewing-stimulated 
whole saliva were collected and the flow rates were 
calculated. The degree of xerostomia was evaluated using 
the Radiation Therapy Oncology Group/European 
Organization for Research and Treatment of Cancer 
(RTOG/EORTC) morbidity score. Mean radiation dose (Gy) 
was registered for both contra- and ipsilateral parotid 
glands. 
Results 
Mean ADC (ADCMean) values and salivary flow rates were 
higher in the stimulated than in the unstimulated state 
(Figure 1a). An increase in ADCmean from scan 1 to scan 3 
both in unstimulated and  
gustatory-stimulated state is observed. Further, the 
unstimulated salivary flow tended to decrease, while 
chewing-stimulated salivary flow decreased between scan 
1 and 2 and increased from scan 2 to scan 3. The 
ADCMean  tended to increase (R^2 = 0.29-0.37), and the 
salivary flow rates to decrease (R^2 = 0.01-0.12), with 
increasing mean radiation dose to the glands (Figures 
1b).  Mean radiation dose to the ipsilateral parotid gland 
was used for the correlation between saliva flow rates and 
mean dose. Figure 1c shows a strong correlation between 
both ADCMean and saliva flow, and the degree of 
xerostomia (R^2 = 0.66-0.97). 
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important to assess the salivary gland function in these 
patients for diagnostic and management purposes. 
The aim of this study is to investigate use of diffusion-
weighted magnetic resonance imaging (DWI) in the 
assessment of radiation-induced microstructural changes 
of the parotid glands in terms of apparent diffusion 
coefficients values (ADC), compared to physiological 
changes in terms of measurements of whole salivary flow 
rates.  It is hypothesized that use of combined methods 
for assessment of parotid gland function, provides further 
insight into the factors that can predict xerostomia. 
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Conclusion 
The results of this pilot study indicate that the severity of 
microstructural and physiological changes of the parotid 
glands after RT is dependent on the mean radiation dose 
to the glands. It also suggests that DWI and salivary flow 
measurements can be used for assessing parotid gland 
function after RT and are associated with degree of 
xerostomia. 
  
EP-1173  Changes in blood pressure in patients 
undergoing radiotherapy for head and neck cancers 
A. Nachankar1, P. Dandekar1 
1Sir H N Reliance Foundation Hospital and Research 
Center, Radiation Oncology, Mumbai, India  
 
Purpose or Objective 
Head and neck cancer patients undergoing radiotherapy 
often complain of fatigue, generalized weakness, light 
headedness associated with poor nutrition, weight loss, 
dehydration and vasomotor changes. Various theories are 
proposed for vasomotor imbalance  
including   neurochemical causes, direct damage to 
carotid body due to radiation or effect on vasomotor 
centers in brainstem, effect of chemotherapy. Hence, we 
studied pattern of blood pressure (BP) changes in head and 
radiotherapy patients. 
Material and Methods 
Patients with head and neck cancer, with ECOG 0-1 
receiving radiotherapy to head and neck region to a dose 
of 60-70 Gy over period of 6-7 weeks from December 2016 
to Feb 2018. We recorded blood pressure of patients, pre-
radiotherapy, weekly during radiotherapy and 
postradiotherapy at 3-6 monthly interval. Patient 
symptoms were documented at the same time. We also 
contoured carotid body region to see document doses. 
Results 
We analyzed 60 patients of head and neck cancers 
receiving radiotherapy to head and neck region, 34 
patients received concurrent chemotherapy.  Thirty-two 
patients received radiotherapy to bilateral neck. Twenty 
four out of 60 patients were hypertensive at baseline and 
were on antihypertensive medications and all patients 
continued their antihypertensive treatment. Only one 
patient had history of hypotension in the past. Average 
weight loss during radiotherapy was 4.1%. We found that 
there was statistically significant decline in blood pressure 
from 3rd to 6th week of radiotherapy in both systolic and 
diastolic blood pressure. Maximum average BP decline till 
5th week of radiotherapy from baseline 132 +/-13 / 78+/-
7 mm of Hg to 115+/-16 /71+/-9 mm of Hg (P<0.05). 
Compared baseline there was significant decline in blood 
pressure from 132 +/-13 / 78+/-7 mm of Hg to 121+/-14 / 
75+/-7 at 3 to 6 months post radiotherapy (P<0.05). Very 
few patients complained of orthostatic hypotension. Mean 
doses to carotid body region were 62.45 +/- 4 Gy. 
Conclusion 
There is a significant decline in BP recorded during in 
patient undergoing head and neck radiotherapy the effect 
of which was persistant upto 6 months after radiotherapy. 
Maximum decline observed upto 5th week of treatment. 
Hence, it is worthwhile to monitor BP during and after 
treatment and appropriate intervention to be taken.  
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Purpose or Objective 
Nausea (N) and dysgeusia (Dg) are common side effects 
occurring during treatment in HN cancer patients, in case 
of either exclusive radiotherapy (RT) or combined 
modality treatment (CMT). Patients’ daily living can be 
significantly affected by N/Dg, with a subsequent 
worsening of treatment compliance. We prospectively 
scored nausea and we employed an 18-item CiTAS 
(chemotherapy (CT)- induced taste alteration scale) 
questionnaire to evaluate 4 taste dimensions identified 
through factor analysis: decline in basic taste, discomfort, 
phantogeusia-parageusia, and general alterations.  
Material and Methods 
Between 2016 and 2018, 31 patients were treated with 
Volumetric Modulated Arc Therapy (VMAT) in the HN 
region within a definitive or adjuvant setting (RT or CMT, 
6 or 7 weeks overall treatment time). All patients were 
given ‘Naumix/Naugin’ (GAMfarma, Milan, Italy)  a spray, 
containing ginger, anise and vitamin B6 as a prophylactic 
approach to prevent N/Dg. CiTAS scale was evaluated at 
baseline (Bs), every week of treatment and during follow-
up at 2 adjunctive time-points (1 week and 1 month after 
RT end). 
Results 
Patients were aged 64 (range 34–83) with mostly male sex 
(61.3%). Most represented tumor subsite was oropharynx 
(25.9%). Most common histology was SCC (77.4%). Patients 
were mainly staged as T1–T2 disease (58%); N0(19%), N1-
3(71%). RT was delivered as definitive (38.7%) or adjuvant 
(61.3%) treatment with prescribed doses ranging from 54 
to 70 Gy. Acute toxicities were generally mild. Grade 1 
nausea was reported by 6.5% of patients at Bs, reaching 
the maximum value during the VI week (38.7%). No patient 
referred ≥ G2 nausea at Bs, while this endpoint  peaked up 
at III week (13% of patients)  with an optimal recovery in 
most of the patients with antiemetic drugs (Tab.1).  
 
